Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01325337 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 307
- Enrollment target
NCT01325337: Completed Phase 2 study, sponsored by Allergan.
NCT01325337 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 307 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (131% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01325337, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 307 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.
Primary Outcome
TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm\^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs).
Interventions
- DRUG bimatoprost vehicle solution
- DRUG bimatoprost Formulation A
- DRUG bimatoprost Formulation B
- DRUG bimatoprost Formulation C
- DRUG minoxidil 5% solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
What the finished NCT01325337 record still lists
NCT01325337 is an interventional study that assigns participants to a tested intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (131% higher).
The record links to 0 conditions, and to 5 interventions - of which bimatoprost vehicle solution is the first listed.
NCT01325337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01325337 about?
NCT01325337 is a clinical study titled "Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia". This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provi...
What is the current status of trial NCT01325337?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 307 participants. The study started on 2011-06. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01325337?
The interventions under investigation include: bimatoprost vehicle solution (DRUG), bimatoprost Formulation A (DRUG), bimatoprost Formulation B (DRUG), bimatoprost Formulation C (DRUG), minoxidil 5% solution (DRUG).
Who is sponsoring clinical trial NCT01325337?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01325337's enrollment target sits among peer trials
307 165th of 2000 higher than 1,836 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05433142 · 307 participants · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia